BWA
NBIX icon

BDO Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

BDO Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25
Closed -$3K – 597
2018
Q3 		$3K Hold
25
– – ﹤0.01% 535
2018
Q2 		$2K Buy
+25
New +$2.24K ﹤0.01% 590

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BDO Wealth Advisors's NBIX Position: Q4 2018 in Review

BDO Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 25 shares — an estimated $3K sold.

BDO Wealth Advisors first reported a position in NBIX in Q2 2018 and held it in 2 quarters. The position peaked at $3K in Q3 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

  • BDO Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
  • BDO Wealth Advisors sold 25 Neurocrine Biosciences shares in Q4 2018, an estimated $3K.
  • BDO Wealth Advisors first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 2 quarters.
  • BDO Wealth Advisors's Neurocrine Biosciences position peaked at $3K in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on BDO Wealth Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.